Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations

David M. Hyman; Ben Tran; Luis Paz-Ares; Jean-Pascal Machiels; Jan H. Schellens; Philippe L. Bedard; Mario Campone; Philippe A. Cassier; John Sarantopoulos; Ulka Vaishampayan; Rashmi Chugh; Amit Mahipal; A. Craig Lockhart; Cristiana Sessa; Thomas Zander; Matthew Ng; Giuseppe Curigliano; Jennifer Bendiske; Xueying Chen; Somesh Choudhury; Diana Graus-Porta; Nancy Lewis; Jose Manuel Perez Garcia; María José de Miguel-Luken

Journal ArticleOPEN ACCESS

Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations

Hyman D
Tran B
Paz-Ares L
et al.

JCO Precision Oncology (2019) (3) 1-13

DOI: 10.1200/po.19.00221

32Citations

41Readers

Get full text

Abstract

PURPOSEConcurrent PIK3CA mutations and fibroblast growth factor receptor (FGFR) alterations occur in multiple cancer types, including estrogen receptor–positive breast cancer, bladder cancer, and e...

Cite

CITATION STYLE

APA

Hyman, D. M., Tran, B., Paz-Ares, L., Machiels, J.-P., Schellens, J. H., Bedard, P. L., … de Miguel-Luken, M. J. (2019). Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations. JCO Precision Oncology, (3), 1–13. https://doi.org/10.1200/po.19.00221

Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations

Abstract

Cite

Register to see more suggestions